Quote from VigiServe Admin on February 10, 2026, 9:11 AM

In Tonga, the pharmacovigilance system is non-operational and relies on ad-hoc support from the WHO Pacific Regional Office and CARPHA (utilizing the VigiCarib platform). There is no dedicated national center or enforceable legislation for safety monitoring.

1. Clinical Safety (Clinical Trials)

Clinical trials are extremely rare and typically humanitarian.

• Framework: No national guidelines; sponsors follow international standards (ICH E2A).

• Expedited Reporting: Sponsors generally follow 7 days (fatal/life-threatening) and 15 days (other serious unexpected) for SUSARs as a matter of best practice.

• Submission: Reports go directly to the Ministry of Health (MoH).

2. Post-Marketing Pharmacovigilance

There are no enforceable local obligations for Marketing Authorization Holders.

• Personnel & Infrastructure:

  • No Local QPPV: Not required.

  • No PSMF Mandate: Not required.

• Incident Reporting (ICSRs):

  • Enforcement: Voluntary/Spontaneous.

  • Practice: Reporting is negligible; serious ADRs are expected "promptly" but handled ad-hoc.

• Risk & Periodic Reporting:

  • PSURs/RMPs: Not required.

Summary of Requirements

Component	Requirement in Tonga
Regulatory Authority	MoH (Ministry of Health)
Regional Framework	WHO Pacific / VigiCarib
Local QPPV / PSMF	Not required
Safety Reporting	None / Ad-hoc
Clinical Reporting	SUSARs (7/15 days - International practice)
Submission Language	English